Other

Orion-yhtyma Oy

Oy Juvantia Pharma Ltd.

Mika Scheinin

Jukka T Salonen

Juha-Matti Savola

Antti Haapalinna

Ullamari Pesonen

Matti Karvonen

Markku Koulu

Tomi-Pekka Tuomainen

Jukka Sallinen

Timo Viitamaa

Veli-Pekka Valkonen

Pia Alhopuro

Mervyn Maze

Paula Heinonen

Amir Snapir

Kristiina Nyyss&ouml;nen

Timo A Lakka

Riitta Salonen

Jussi Kauhanen

This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant &agr; -adrenoceptor protein and to the variant &agr; -adrenoceptor protein as well as a method for screening a subject to determine if the subject is a carrier of a variant gene that encodes the variant &agr; -adrenoceptor protein. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries, the method comprising the step of administering a selective &agr; -adrenoceptor antagonist to the mammal and to transgenic animals comprising a human DNA molecule encoding human &agr; -adrenoceptor protein or the variant &agr; -adrenoceptor protein.

DNA molecule encoding a variant &agr;2B-adrenoceptor protein, and uses thereof

The invention relates to a method for treating a mammal suffering from mental illness induced by propagation of stress, said method comprising the step of removing or diminishing the tone of the endogenous alpha-2C-adrenoceptors in the central nervous system of said mammal. The invention relates further to pharmaceutical compositions useful for said treatment.

Method for the treatment of mental illness in mammals and a composition

4-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole, known as medetomidine, and in particular its d-enantiomer and salts thereof are useful in perioperative care, in particular in reducing the amount of anaesthetic it is necessary to administer.

4-substituted imidazole derivatives useful in perioperative care

Growing community of inventors

Naantali, Finland

Mika Scheinin